Year |
Citation |
Score |
2023 |
Mukherjee D, Previs RA, Haines C, Al Abo M, Juras PK, Strickland KC, Chakraborty B, Artham S, Whitaker RS, Hebert K, Fontenot J, Patierno SR, Freedman JA, Lau FH, Burow ME, et al. Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis. Cancer Research. PMID 37335130 DOI: 10.1158/0008-5472.CAN-22-1622 |
0.316 |
|
2022 |
Zhang S, Mao M, Lv Y, Yang Y, He W, Song Y, Wang Y, Yang Y, Al Abo M, Freedman JA, Patierno SR, Wang Y, Wang Z. A widespread length-dependent splicing dysregulation in cancer. Science Advances. 8: eabn9232. PMID 35977015 DOI: 10.1126/sciadv.abn9232 |
0.412 |
|
2022 |
Odera JO, Abo MA, Patierno SR, Clarke JM, Freedman JA. Changing the landscape of non-small cell lung cancer disparities. Journal of Cancer Biology. 2: 33-38. PMID 35929605 DOI: 10.46439/cancerbiology.2.020 |
0.314 |
|
2022 |
Al Abo M, Gearhart-Serna L, Van Laere S, Freedman JA, Patierno SR, Hwang ES, Krishnamurthy S, Williams KP, Devi GR. Adaptive stress response genes associated with breast cancer subtypes and survival outcomes reveal race-related differences. Npj Breast Cancer. 8: 73. PMID 35697736 DOI: 10.1038/s41523-022-00431-z |
0.325 |
|
2021 |
Patierno BM, Foo WC, Allen T, Somarelli JA, Ware KE, Gupta S, Wise S, Wise JP, Qin X, Zhang D, Xu L, Li Y, Chen X, Inman BA, McCall SJ, ... ... Freedman JA, et al. Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry. Prostate Cancer and Prostatic Diseases. PMID 34645983 DOI: 10.1038/s41391-021-00460-y |
0.533 |
|
2021 |
George DJ, Halabi S, Heath EI, Sartor AO, Sonpavde GP, Das D, Bitting RL, Berry W, Healy P, Anand M, Winters C, Riggan C, Kephart J, Wilder R, Shobe K, ... ... Freedman JA, et al. A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. Cancer. PMID 33951180 DOI: 10.1002/cncr.33589 |
0.456 |
|
2021 |
Al Abo M, Hyslop T, Qin X, Owzar K, George DJ, Patierno SR, Freedman JA. Differential alternative RNA splicing and transcription events between tumors from African American and white patients in The Cancer Genome Atlas. Genomics. PMID 33705884 DOI: 10.1016/j.ygeno.2021.02.020 |
0.395 |
|
2021 |
Freedman JA, Al Abo M, Allen TA, Piwarski SA, Wegermann K, Patierno SR. Biological Aspects of Cancer Health Disparities. Annual Review of Medicine. 72: 229-241. PMID 33502900 DOI: 10.1146/annurev-med-070119-120305 |
0.333 |
|
2020 |
Williams KP, Barrett NJ, Oldham CE, Hough H, Woodard A, Freedman J, Devi GR, Patierno SR. Abstract IA18: North Carolina Central University and Duke Cancer Institute's collaborative cancer research and education program: Connecting cancer disparities translational research, clinical trials operations, and community engagement Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-Ia18 |
0.322 |
|
2019 |
Robinson TJ, Freedman JA, Al Abo M, Deveaux AE, LaCroix B, Patierno BM, George DJ, Patierno SR. Alternative RNA Splicing as a Potential Major Source of Untapped Molecular Targets in Precision Oncology and Cancer Disparities. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30755441 DOI: 10.1158/1078-0432.Ccr-18-2445 |
0.384 |
|
2018 |
Freedman JA, Wang Y, Li X, Liu H, Moorman PG, George DJ, Lee NH, Hyslop T, Wei Q, Patierno SR. Single Nucleotide Polymorphisms of Stemness Genes Predicted to Regulate RNA Splicing, microRNA and Oncogenic Signaling are Associated with Prostate Cancer Survival. Carcinogenesis. PMID 29726910 DOI: 10.1093/Carcin/Bgy062 |
0.403 |
|
2018 |
Deveaux A, Wang B, Lacroix B, Patierno B, Zhang D, Owzar K, Lee N, George D, Freedman J, Patierno S. Abstract B59: Race-related differential splicing of the insulin receptor: A novel target underlying prostate cancer disparities Cancer Epidemiology, Biomarkers & Prevention. 27. DOI: 10.1158/1538-7755.Disp17-B59 |
0.47 |
|
2018 |
Patierno B, Glover W, Ribar T, Kittles R, Foo W, McCall S, Huang J, George D, Freedman J, Patierno S, Wood K, Hsu D. Abstract A79: Establishment of African American prostate cancer patient-derived primary cell lines and xenografts Cancer Epidemiology, Biomarkers & Prevention. 27. DOI: 10.1158/1538-7755.Disp17-A79 |
0.433 |
|
2017 |
Wang BD, Ceniccola K, Hwang S, Andrawis R, Horvath A, Freedman JA, Olender J, Knapp S, Ching T, Garmire L, Patel V, Garcia-Blanco MA, Patierno SR, Lee NH. Corrigendum: Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer. Nature Communications. 8: 16161. PMID 28952599 DOI: 10.1038/Ncomms16161 |
0.443 |
|
2017 |
Wang BD, Ceniccola K, Hwang S, Andrawis R, Horvath A, Freedman JA, Olender J, Knapp S, Ching T, Garmire L, Patel V, Garcia-Blanco MA, Patierno SR, Lee NH. Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer. Nature Communications. 8: 15921. PMID 28665395 DOI: 10.1038/Ncomms15921 |
0.487 |
|
2017 |
Wang Y, Freedman JA, Liu H, Moorman PG, Hyslop T, George DJ, Lee NH, Patierno SR, Wei Q. Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. International Journal of Cancer. PMID 28510291 DOI: 10.1002/Ijc.30787 |
0.459 |
|
2016 |
Ramalingam S, Eisenberg A, Foo WC, Freedman J, Armstrong AJ, Moss LG, Harrison MR. Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 27766686 DOI: 10.1111/Iju.13225 |
0.452 |
|
2016 |
Longo T, McGinley KF, Freedman JA, Etienne W, Wu Y, Sibley A, Owzar K, Gresham J, Moy C, Szabo S, Greshock J, Zhou H, Bai Y, Inman BA. Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer. European Urology. PMID 27520487 DOI: 10.1016/J.Eururo.2016.07.049 |
0.319 |
|
2016 |
Ware KE, Somarelli JA, Schaeffer D, Li J, Zhang T, Park S, Patierno SR, Freedman J, Garcia-Blanco MA, Armstrong AJ. Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer. Oncotarget. PMID 27409172 DOI: 10.18632/Oncotarget.10476 |
0.447 |
|
2012 |
Kim MK, Osada T, Barry WT, Yang XY, Freedman JA, Tsamis KA, Datto M, Clary BM, Clay T, Morse MA, Febbo PG, Lyerly HK, Hsu DS. Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer. Molecular Cancer Therapeutics. 11: 1500-9. PMID 22351745 DOI: 10.1158/1535-7163.Mct-11-0937 |
0.33 |
|
Show low-probability matches. |